QLC5508
QLC5508 is an experimental antibody-drug conjugate from Qilu Pharmaceutical in phase 3 trials for oesophageal cancer, prostate cancer and non-small-cell lung cancer, aimed at B7-H3.
Overview
QLC5508 (MHB088C) is an antibody-drug conjugate developed by Qilu Pharmaceutical and Minghui Pharmaceutical (Hangzhou). Its target is B7-H3. ClinicalTrials.gov describes the intervention as: B7H3 ADC; QLC5508 will be administered by injection at the dose and dosing frequency specified in the protocol. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07463573 (QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Oesophageal Squamous Cell Carcinoma) and NCT06954246 (A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer), in oesophageal cancer, prostate cancer and non-small-cell lung cancer. The largest, NCT07102004, plans to enrol 515 participants with primary completion expected 2026-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"QLC5508" OR ABSTRACT:"QLC5508" OR TITLE:"MHB088C" OR ABSTRACT:"MHB088C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about QLC5508, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentBNT324
Shares B7-H3, Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentQLH12016
Shares Qilu Pharmaceutical, Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentQL2107
Shares Qilu Pharmaceutical, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentYL201
Shares B7-H3, Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentBCB-276
Shares B7-H3 and the tags pipeline, ctgov-ingest.
- TreatmentTQB6411
Shares Oesophageal cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentQL1706
Shares Qilu Pharmaceutical, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentHS-20093
Shares Oesophageal cancer, Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.